Entresto failure to launch

A bullshit drug is hard to sell. Putting a new dress on the old whore doesn't make her desire able again. Back to the drawing board

 

The data is not great compared to the standard of care. Are the doctors still upset over Tekturna and Valturna and there bogus studies, I think so. Manage care decides if the drug is worth it if it keeps patients out of the hospital great but it seems they see through the scam.
Novartis also cannot bundle its Diovan to get it on formulary, so good selling

 

You're off of the mark.. nice try..